Current Highlight from May 13, 2016
Role of Drug Metabolism in Amiodarone-Induced Liver Injury
NCTR scientists have shown that metabolism of amiodarone (an anti-arrhythmic drug) by cytochrome P450 (CYP) isoforms 3A4 and 1A1 is linked to its observed hepatotoxicity. A panel of HepG2-derived cell lines that stably express 14 individual human CYPs were treated with clinically relevant concentrations of amiodarone and assayed for cell viability. Increased toxicity and higher levels of the hepatotoxic metabolite desethylamiodarone were observed in the cell lines overexpressing CYP3A4 and CYP1A1. Amiodarone is a commonly used anti-arrhythmic drug that is often associated with numerous adverse effects, including liver injury; however, the mechanisms of this toxicity are not well understood. These results, together with the well-known inter-individual variation in CYP3A4 expression levels, could affect the clinical use of amiodarone. A manuscript reporting the study is available online at Toxicology Letters.
For additional information, please contact Matthew Bryant, Lei Guo, Division of Biochemical Toxicology, FDA/NCTR.
No hay comentarios:
Publicar un comentario